Is Towa Pharmaceutical Europe, S.L. FDA approved?

Towa Pharmaceutical Europe, S.L. holds 1 FDA-registered establishment in Spain. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.

Where are Towa Pharmaceutical Europe, S.L.'s drugs manufactured?

The FDA register lists Martorelles. Registered operations: analytical testing, finished drug manufacture.

What drugs does Towa Pharmaceutical Europe, S.L. make?

6 products are listed under Towa Pharmaceutical Europe, S.L. in the openFDA NDC Directory, most often as capsule, delayed release pellets. The full breakdown by dosage form and route is above. A listing count is not a sales figure.

Towa Pharmaceutical Europe, S.L.

Data as of 24 Sept 2026 · How to read this entry

Request a quote Claim this profile

Registered sites: 1
Active NDC listings: 6
Live patents: 0
Countries: 1
Base: Spain

Authorisation

Registered operations

Analytical testing1Finished drug manufacture1

Sites

Registered establishments

Establishment	Address	Registered for	FEI / DUNS
Towa Pharmaceutical Europe, S.L.	Calle de Sant Marti, 75-97, Martorelles, 08107, Spain (ESP)	Analytical testing, Finished drug manufacture	3003121577467833930

Catalogue

Drug listings by form and route

6 active NDC listings: 6 drug for further processing. By marketing category: DRUG FOR FURTHER PROCESSING 6.

Dosage form	NDCs
capsule, delayed release pellets	6

Route	NDCs

Labeller name on the listing	NDCs
towa pharmaceutical europe, s.l.	6

Catalogue

Marketed products

Brand	Generic name	Form / route	NDC
-	DULOXETINE HYDROCHLORIDE	capsule, delayed release pellets	73476-746DRUG FOR FURTHER PROCESSING
-	DULOXETINE HYDROCHLORIDE	capsule, delayed release pellets	73476-747DRUG FOR FURTHER PROCESSING
-	DULOXETINE HYDROCHLORIDE	capsule, delayed release pellets	73476-748DRUG FOR FURTHER PROCESSING
-	DULOXETINE HYDROCHLORIDE	capsule, delayed release pellets	73476-750DRUG FOR FURTHER PROCESSING
-	OMEPRAZOLE	capsule, delayed release pellets	73476-643DRUG FOR FURTHER PROCESSING
-	OMEPRAZOLE	capsule, delayed release pellets	73476-644DRUG FOR FURTHER PROCESSING

Compare

Comparable companies in Spain

QUIMICA SINTETICA SA1 site · 58 NDC
Derivados Quimicos SAU1 site · 38 NDC
Interquim, S.A.1 site · 26 NDC
Farmhispania S.A.1 site · 17 NDC
Rolabo Outsourcing S.L.1 site · 9 NDC
AGC Pharma Chemicals Europe, S.L.U .1 site · 7 NDC
BERIOSKA SL1 site · 7 NDC
Ercros SA1 site · 7 NDC
Quality Chemicals S.L.1 site · 3 NDC
AVIZOR, S.A.1 site · 2 NDC

Enquiry

Common questions

Is Towa Pharmaceutical Europe, S.L. FDA approved?: Towa Pharmaceutical Europe, S.L. holds 1 FDA-registered establishment in Spain. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
Where are Towa Pharmaceutical Europe, S.L.'s drugs manufactured?: The FDA register lists Martorelles. Registered operations: analytical testing, finished drug manufacture.
What drugs does Towa Pharmaceutical Europe, S.L. make?: 6 products are listed under Towa Pharmaceutical Europe, S.L. in the openFDA NDC Directory, most often as capsule, delayed release pellets. The full breakdown by dosage form and route is above. A listing count is not a sales figure.

Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.